| __timestamp | Exelixis, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 50829000 | 44820000 |
| Thursday, January 1, 2015 | 57305000 | 82080000 |
| Friday, January 1, 2016 | 116145000 | 97130000 |
| Sunday, January 1, 2017 | 159362000 | 121271000 |
| Monday, January 1, 2018 | 206366000 | 153548000 |
| Tuesday, January 1, 2019 | 228244000 | 202541000 |
| Wednesday, January 1, 2020 | 293355000 | 245164000 |
| Friday, January 1, 2021 | 401715000 | 285773000 |
| Saturday, January 1, 2022 | 459856000 | 325998000 |
| Sunday, January 1, 2023 | 542705000 | 332540000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, Exelixis, Inc. and PTC Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Exelixis, Inc. experienced a staggering 967% increase in SG&A expenses, reflecting its aggressive expansion and operational scaling. In contrast, PTC Therapeutics, Inc. saw a 642% rise, indicating steady growth and strategic investments.
By 2023, Exelixis, Inc.'s SG&A expenses reached approximately 54 million, surpassing PTC Therapeutics, Inc.'s 33 million by a significant margin. This divergence highlights Exelixis, Inc.'s robust market positioning and commitment to innovation. As these companies continue to evolve, monitoring their financial strategies will provide valuable insights into their future trajectories and the broader biotech sector.
Who Optimizes SG&A Costs Better? Vertex Pharmaceuticals Incorporated or Exelixis, Inc.
Cost of Revenue: Key Insights for Exelixis, Inc. and PTC Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alkermes plc
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and CRISPR Therapeutics AG
Exelixis, Inc. and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Exelixis, Inc. or Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
PTC Therapeutics, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?